Vildagliptin

Endocrine Today has compiled a list of breaking drug trial news reports posted from the annual meeting of the European Association for the Study of Diabetes Annual Meeting.

Among a cohort of adults with recent type 2 diabetes prescribed metformin, those assigned to receive vildagliptin as an add-on therapy maintained better long-term glycemic control than those who continued on monotherapy, according to findings from the VERIFY trial presented at the European Association for the Study of Diabetes annual meeting and simultaneously published in The Lancet.

Adults with type 2 diabetes who are treated with DPP-IV inhibitors are more likely to develop pancreatitis and pancreatic cancer compared with those treated with other medications, according to findings published in Diabetes Care.